The Montreal Heart Institute (MHI) is expanding enrollment in a clinical trial testing a new drug for COVID-19 treatment.
The Colchicine Coronavirus SARS-CoV-2 (COLCORONA) Trial is testing the use of colchicine for the disease. The drug has traditionally been used to treat gout, the institute said.
The trial includes recently diagnosed, nonhospitalized adults with COVID-19, and included participants from Canada, Europe, South America, South Africa, and the U.S.
Patients and physicians interested in the trial can visit its website, the institute said.
